Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT01476410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma
Study identification
- NCT ID
- NCT01476410
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Northwestern University
- Other
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- DNA analysis Genetic
- RNA analysis Genetic
- brentuximab vedotin Drug
- dacarbazine Drug
- doxorubicin hydrochloride Drug
- fludeoxyglucose F 18 Radiation
- immunohistochemistry staining method Other
- laboratory biomarker analysis Other
- polymorphism analysis Genetic
- positron emission tomography Procedure
- quality-of-life assessment Procedure
- vinblastine Drug
Genetic · Drug · Radiation + 2 more
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Apr 30, 2021
- Completion
- Apr 30, 2021
- Last update posted
- Feb 16, 2020
2011 – 2021
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Medical Center | Stanford | California | 94305 | — |
| NorthwesternU | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198-7835 | — |
| Memorial Sloan- Kettering Cancer Center | New York | New York | 10065 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01476410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2020 · Synced Apr 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01476410 live on ClinicalTrials.gov.